Site dependent bioavailability and metabolism of levosimendan in dogs

被引:53
作者
Antila, S
Huuskonen, H
Nevalainen, T
Kanerva, H
Vanninen, P
Lehtonen, L
机构
[1] Orion Phamaceut Co, Espoo 02101, Finland
[2] Natl Publ Hlth Inst, Div Environm Hlth, Kuopio, Finland
[3] Univ Kuopio, Natl Lab Anim Ctr, FIN-70211 Kuopio, Finland
关键词
levosimendan; bioavailability; pharmacokinetics; metabolism;
D O I
10.1016/S0928-0987(99)00048-2
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Site specific bioavailability and metabolism of levosimendan was studied in ten dogs by placing intestinal access port catheters in different parts of the gastrointestinal tract. C-14-labelled levosimendan (0.1 mg/kg) was administered intravenously, by gastric tube and directly through catheters that were placed in the duodenum, jejunum and ileum. Plasma samples were collected and radioactivity in the different organs and tissues was measured. The results of the present study showed that bioavailability of levosimendan was high varying from 71 to 86% after extravascular administration. Metabolite OR-1855 concentrations in the plasma were about 3-4 times higher after administration to the ileum compared to the other administration routes. It can be concluded that the bioavailability of levosimendan is not affected by site specific administration. The bacteria or enzymes responsible for the metabolism of levosimendan are located in the lower parts of the gastrointestinal tract. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:85 / 91
页数:7
相关论文
共 12 条
[1]
Antila S, 1997, ARZNEIMITTEL-FORSCH, V47, P816
[2]
KANERVA H, 1997, PHARMACOL RES S, V14, P668
[3]
Karlsson M, 1997, BIOMED CHROMATOGR, V11, P54, DOI 10.1002/(SICI)1099-0801(199701)11:1<54::AID-BMC629>3.3.CO
[4]
2-C
[5]
Lemaire M, 1991, Eur J Drug Metab Pharmacokinet, VSpec No 3, P132
[6]
MEUNIER LD, 1993, LAB ANIM SCI, V43, P466
[7]
POLLESELLO P, 1994, J BIOL CHEM, V269, P28584
[8]
IMPROVED INTESTINAL CANNULA FOR DRUG DELIVERY STUDIES IN THE DOG [J].
RUBINSTEIN, A ;
LI, VHK ;
GRUBER, P ;
BASS, P ;
ROBINSON, JR .
JOURNAL OF PHARMACOLOGICAL METHODS, 1988, 19 (03) :213-217
[9]
Sandell EP, 1995, J CARDIOVASC PHARM, V26, pS57
[10]
Sundberg S, 1998, INT J CLIN PHARM TH, V36, P629